SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

SEC Comment Letter 0000000000-24-002924 to Solid Biosciences Inc. (SLDB)

Solid Biosciences Inc.
Date: March 18, 2024 · CIK: 0001707502 · Accession: 0000000000-24-002924

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-277871

Date
March 18, 2024
Author
Bo Cumbo
Form
UPLOAD
Company
Solid Biosciences Inc.

Letter

United States securities and exchange commission logo March 18, 2024 Bo Cumbo Chief Executive Officer Solid Biosciences Inc. 500 Rutherford Avenue, Third Floor Charlestown, MA 02129 Re:Solid Biosciences Inc. Registration Statement on Form S-3 Filed March 13, 2024 File No. 333-277871 Dear Bo Cumbo: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jimmy McNamara at 202-551-7349 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Caroline Dotolo

Show Raw Text
United States securities and exchange commission logo
March 18, 2024
Bo Cumbo
Chief Executive Officer
Solid Biosciences Inc.
500 Rutherford Avenue, Third Floor
Charlestown, MA 02129
Re:Solid Biosciences Inc.
Registration Statement on Form S-3
Filed March 13, 2024
File No. 333-277871
Dear Bo Cumbo:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Jimmy McNamara at 202-551-7349 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Caroline Dotolo